CYCN Stock - Cyclerion Therapeutics, Inc.
Unlock GoAI Insights for CYCN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.00M | N/A | $297,000 | $3.32M | $2.30M |
| Gross Profit | $2.00M | N/A | $-5,282,000 | $3.32M | $-54,118,000 |
| Gross Margin | 100.0% | N/A | -1778.5% | 100.0% | -2357.1% |
| Operating Income | $-3,628,000 | $-12,951,000 | $-18,540,000 | $-55,195,000 | $-81,265,000 |
| Net Income | $-3,057,000 | $-5,263,000 | $-44,078,000 | $-51,647,000 | $-77,802,000 |
| Net Margin | -152.8% | N/A | -14841.1% | -1555.6% | -3388.6% |
| EPS | $-1.21 | $-8.99 | $-20.15 | $-26.40 | $-47.80 |
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Visit WebsiteEarnings History & Surprises
CYCNEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Mar 2, 2026 | — | — | — | — |
Q4 2025 | Nov 12, 2025 | — | $-0.30 | — | — |
Q3 2025 | Aug 5, 2025 | — | $-0.11 | — | — |
Q2 2025 | May 6, 2025 | — | $-0.56 | — | — |
Q1 2025 | Mar 4, 2025 | — | $0.22 | — | — |
Q4 2024 | Nov 14, 2024 | — | $-0.29 | — | — |
Q3 2024 | Aug 7, 2024 | — | $-0.53 | — | — |
Q2 2024 | May 7, 2024 | — | $-0.62 | — | — |
Q1 2024 | Mar 5, 2024 | $-7.40 | $-0.68 | +90.7% | ✓ BEAT |
Q4 2023 | Nov 13, 2023 | $-6.40 | $-0.93 | +85.5% | ✓ BEAT |
Q3 2023 | Jul 28, 2023 | $-5.60 | $-1.83 | +67.3% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-6.00 | $-3.20 | +46.7% | ✓ BEAT |
Q1 2023 | Mar 22, 2023 | $-5.80 | $-3.20 | +44.8% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $-7.00 | $-4.80 | +31.4% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-6.80 | $-6.20 | +8.8% | ✓ BEAT |
Q2 2022 | May 4, 2022 | $-7.20 | $-6.00 | +16.7% | ✓ BEAT |
Q1 2022 | Feb 24, 2022 | $-6.40 | $-4.80 | +25.0% | ✓ BEAT |
Q4 2021 | Nov 9, 2021 | $-5.80 | $-5.20 | +10.3% | ✓ BEAT |
Q3 2021 | Jul 29, 2021 | — | $-9.00 | — | — |
Latest News
Cyclerion Therapeutics Says Under License Agreement, MIT Eligible For Up To $4.4M In Milestone Payments
📈 PositiveCyclerion Therapeutics shares are trading higher after the company announced it entered into a licensing agreement with MIT as part of its strategic relaunch.
📈 PositiveCyclerion Announces License Agreement With MIT To Relaunch Advancing Phase 2–Ready Treatment For Resistant Depression
📈 PositiveFrequently Asked Questions about CYCN
What is CYCN's current stock price?
What is the analyst price target for CYCN?
What sector is Cyclerion Therapeutics, Inc. in?
What is CYCN's market cap?
Does CYCN pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to CYCN for comparison